medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2018, Number 1

<< Back Next >>

Rev Latin Infect Pediatr 2018; 31 (1)

Antiphospholipid syndrome in a one-month-old patient. Case report on a Latin American infant and literature review

Moya-Barquín LA, Coronel-Martínez DL, Arredondo-García JL

Language: Spanish
References: 18
Page: 36-39
PDF size: 399.45 Kb.


ABSTRACT

Background: The real antiphospholipid syndrome (APS) prevalence is unknown. The SAF clinical spectrum includes: positivity to antiphospholipid antibodies (aPL) without clinical data, positive aPL with non-trombotic manifestations, vascular thrombosis based SAF and y catastrophic SAF. Case report: One month and seven days old boy that presented clinical data of thrombosis, with purple colored lesions, Raynaud’s phenomenonpor and profound cianosis in the left upper extremity and inferior extremities; with thrombocytopenia and positive lupic anticoagulant; SAF was clinical diagnosed, requiring mechanic ventilation support, anticoagulant therapy and vasodilators, with good evolution of the lesions, achieving the preservation of the lower limbs (infracondilealleve). The patient had good evolution and was discharged. Conclusion: The classification criteria are useful for clinical research, not for diagnosis. The «non-classic» patients can fall in other clinical SAF spectrum and get lost. SAF in children differs from the adult´s presentation. In a thrombotic event, SAF should be suspected and treated, independently of the laboratory confirmation.


REFERENCES

  1. Aguiar CL, Soybilgic A, Avcin T, Myones BL. Pediatric antiphospholipid syndrome. Curr Rheumatol Rep. 2015; 17 (4): 27.

  2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4 (2): 295-306.

  3. Avcin T, Cimaz R, Silverman ED, Cervera R, Gattorno M, Garay S et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008; 122 (5): e1100-e1107.

  4. Berkun Y, Simchen MJ, Strauss T, Menashcu S, Padeh S, Kenet G. Antiphospholipid antibodies in neonates with stroke--a unique entity or variant of antiphospholipid syndrome? Lupus. 2014; 23 (10): 986-993.

  5. Avcin T, Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep. 2007; 9 (3): 212-218.

  6. Wenzel C, Stoiser B, Locker GJ, Laczika K, Quehenberger P, Kapiotis S et al. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med. 2002; 30 (4): 763-770.

  7. Cruz-Tapias P, Blank M, Anaya JM, Shoenfeld Y. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol. 2012; 24 (4): 389-393.

  8. Avcin T, Ambrozic A, Kuhar M, Kveder T, Rozman B. Anticardiolipin and anti-beta(2) glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology (Oxford). 2001; 40 (5): 565-573.

  9. Blank M, Israeli E, Shoenfeld Y. When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Lupus. 2012; 21 (7): 711-714.

  10. Monastiri K, Selmi H, Tabarki B, Yacoub M, Mahjoub T, Essoussi AS. Primary antiphospholipid syndrome presenting as complicated Henoch-Schönlein purpura. Arch Dis Child. 2002; 86 (2): 132-133.

  11. Gómez-Puerta JA, Martín H, Amigo MC, Aguirre MA, Camps MT, Cuadrado MJ et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore). 2005; 84 (4): 225-230.

  12. Jilma B, Kamath S, Lip GY. ABC of antithrombotic therapy: Antithrombotic therapy in special circumstances. II-In children, thrombophilia, and miscellaneous conditions. BMJ. 2003; 326 (7380): 93-96.

  13. Sanna G, Bertolaccini ML, Hughes GR. Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology. Ann N Y Acad Sci. 2005; 1051: 465-486.

  14. Thornburg C, Pipe S. Neonatal thromboembolic emergencies. Semin Fetal Neonatal Med. 2006; 11 (3): 198-206.

  15. Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994; 83 (5): 1251-1257.

  16. Muscal E, Brey RL. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus. 2010; 19 (4): 406-411.

  17. Gattorno M, Falcini F, Ravelli A, Zulian F, Buoncompagni A, Martini G et al. Outcome of primary antiphospholipid syndrome in childhood. Lupus. 2003; 12 (6): 449-453.

  18. Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014; 13 (6): 685-696.




2020     |     www.medigraphic.com